Drug Type Antibody drug conjugate (ADC) |
Synonyms Anti-CD228-MMAE, anti-CD228 antibody-drug conjugate |
Target |
Mechanism CD228 inhibitors(Melanotransferrin inhibitors), Tubulin inhibitors, Apoptosis stimulants + [1] |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC39H67N5O7 |
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N |
CAS Registry474645-27-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Phase 1 | FR | 03 Sep 2019 | |
Colorectal Cancer | Phase 1 | GB | 03 Sep 2019 | |
Colorectal Cancer | Phase 1 | US | 03 Sep 2019 | |
Colorectal Cancer | Phase 1 | ES | 03 Sep 2019 | |
Colorectal Cancer | Phase 1 | IT | 03 Sep 2019 | |
Melanoma, Cutaneous Malignant | Phase 1 | US | 03 Sep 2019 | |
Melanoma, Cutaneous Malignant | Phase 1 | IT | 03 Sep 2019 | |
Melanoma, Cutaneous Malignant | Phase 1 | FR | 03 Sep 2019 | |
Melanoma, Cutaneous Malignant | Phase 1 | ES | 03 Sep 2019 | |
Melanoma, Cutaneous Malignant | Phase 1 | GB | 03 Sep 2019 |